These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 32815520)

  • 1. Super-selective transarterial chemoembolization of hepatocellular carcinoma with doxorubicin-eluting beads sized 40-75 microns: assessment of efficacy and safety.
    Ballı HT; Aikimbaev K
    Diagn Interv Radiol; 2020 Sep; 26(5):482-487. PubMed ID: 32815520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and effectiveness of chemoembolization with drug-eluting beads for advanced-stage hepatocellular carcinoma.
    Kalva SP; Pectasides M; Liu R; Rachamreddy N; Surakanti S; Yeddula K; Ganguli S; Wicky S; Blaszkowsky LS; Zhu AX
    Cardiovasc Intervent Radiol; 2014 Apr; 37(2):381-7. PubMed ID: 23754191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conventional Versus Small Doxorubicin-eluting Bead Transcatheter Arterial Chemoembolization for Treating Barcelona Clinic Liver Cancer Stage 0/A Hepatocellular Carcinoma.
    Kang YJ; Lee BC; Kim JK; Yim NY; Kim HO; Cho SB; Jeong YY
    Cardiovasc Intervent Radiol; 2020 Jan; 43(1):55-64. PubMed ID: 31646378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imaging Changes and Clinical Complications After Drug-Eluting Bead Versus Conventional Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Multicenter Study.
    Zhang L; Sun JH; Ji JS; Zhong BY; Zhou GH; Song JJ; Hou ZH; Huang P; Zhang S; Li Z; Zhu XL; Ni CF
    AJR Am J Roentgenol; 2021 Oct; 217(4):933-943. PubMed ID: 33245680
    [No Abstract]   [Full Text] [Related]  

  • 5. Survival, efficacy, and safety of small versus large doxorubicin drug-eluting beads TACE chemoembolization in patients with unresectable HCC.
    Prajapati HJ; Xing M; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS
    AJR Am J Roentgenol; 2014 Dec; 203(6):W706-14. PubMed ID: 25415737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Super-Selective Transarterial Chemoembolization with Doxorubicin-Loaded Drug-Eluting Beads Sized Below and Above 100 Microns in Hepatocellular Carcinoma: A Comparative Study.
    Balli H; Aksungur E; Khalatai B; Aikimbaev K
    J Belg Soc Radiol; 2019 Jul; 103(1):47. PubMed ID: 31531413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma.
    Prajapati HJ; Dhanasekaran R; El-Rayes BF; Kauh JS; Maithel SK; Chen Z; Kim HS
    J Vasc Interv Radiol; 2013 Mar; 24(3):307-15. PubMed ID: 23375519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of raltitrexed-eluting CalliSpheres
    Sun Z; Jiao D; Fang Y; Liu Y; Xu K; Zhang C; Huang Y; Han X
    Ther Adv Med Oncol; 2024; 16():17588359241229661. PubMed ID: 38362379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival, tumour response and safety of 70-150 μm versus 100-300 μm doxorubicin drug-eluting beads in transarterial chemoembolisation for hepatocellular carcinoma.
    Huo YR; Xiang H; Chan MV; Chan C
    J Med Imaging Radiat Oncol; 2019 Dec; 63(6):802-811. PubMed ID: 31709778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization by CalliSpheres
    Sun J; Zhou G; Xie X; Gu W; Huang J; Zhu D; Hu W; Hou Q; Shi C; Li T; Zhang X; Ji W; Ying S; Peng Z; Zhou J; Yu Z; Ji J; Du H; Guo X; Fang J; Han J; Xu H; Sun Z; Yu W; Shao G; Wu X; Hu H; Li L; Zheng J; Luo J; Chen Y; Cao G; Hu T
    Oncol Res; 2020 Feb; 28(1):75-94. PubMed ID: 31558180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Drug Eluting Bead TACE with Microspheres <150 μm for the Treatment of Hepatocellular Carcinoma.
    Sattler T; Bredt C; Surwald S; Rust C; Rieger J; Jakobs T
    Anticancer Res; 2018 Feb; 38(2):1025-1032. PubMed ID: 29374736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.
    Liu YS; Lin CY; Chuang MT; Lin CY; Tsai YS; Wang CK; Ou MC
    BMC Gastroenterol; 2018 Aug; 18(1):124. PubMed ID: 30075752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcomes of doxorubicin-eluting CalliSpheres® beads-transarterial chemoembolization for unresectable or recurrent esophageal carcinoma.
    Bi Y; Shi X; Ren J; Yi M; Han X; Song M
    BMC Gastroenterol; 2021 May; 21(1):231. PubMed ID: 34020608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-term efficacy and safety of callispheres drug-loaded microsphere embolization in primary hepatocellular carcinoma.
    Li J; Wang N; Shi C; Liu Q; Song J; Ye X
    J Cancer Res Ther; 2021 Jul; 17(3):733-739. PubMed ID: 34269307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Long-Term Survival Outcome in Patients With Unresectable Barcelona Clinic Liver Cancer (BCLC) Stages C and D Advanced Hepatocellular Carcinoma Treated With 40 μm Drug-Eluting Bead Transcatheter Arterial Chemoembolization.
    Wholey M; Palacios Iii R; Wholey D; Mendez A
    Cureus; 2022 Apr; 14(4):e24047. PubMed ID: 35573558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study.
    Wu B; Zhou J; Ling G; Zhu D; Long Q
    World J Surg Oncol; 2018 Mar; 16(1):69. PubMed ID: 29587773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doxorubicin-loaded drug-eluting beads versus conventional transarterial chemoembolization for nonresectable hepatocellular carcinoma.
    Arabi M; BenMousa A; Bzeizi K; Garad F; Ahmed I; Al-Otaibi M
    Saudi J Gastroenterol; 2015; 21(3):175-80. PubMed ID: 26021777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study.
    Xing M; Webber G; Prajapati HJ; Chen Z; El-Rayes B; Spivey JR; Pillai AA; Kim HS
    J Gastroenterol Hepatol; 2015 Jul; 30(7):1167-74. PubMed ID: 25675849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between SACE (Subjective Angiographic Chemoembolization Endpoint) score and tumor response and its impact on survival after DEB-TACE in patients with hepatocellular carcinoma.
    Habbel VSA; Zeile M; Stavrou GA; Wacker F; Brüning R; Oldhafer KJ; Rodt T
    Abdom Radiol (NY); 2019 Oct; 44(10):3463-3479. PubMed ID: 31332502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of survival and prognostic factors in treatment of hepatocellular carcinoma in Spanish patients with drug-eluting bead transarterial chemoembolization.
    Sánchez-Delgado J; Vergara M; Machlab S; Lira A; Gómez Zaragoza C; Criado E; Rosinach M; Batista L; Arau B; Roget M; Ortiz J; Garcia C; Sort P; Casas M; Dalmau B; Forné M; Falcó J; Miquel M
    Eur J Gastroenterol Hepatol; 2018 Dec; 30(12):1453-1460. PubMed ID: 30113926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.